Bass Bailey B, Vann Lacey J
Mental Health Clinical Pharmacist Practitioner, Mental Health Department, Ralph H. Johnson Veterans Affairs Medical Center, Savannah, Georgia.
Ment Health Clin. 2024 Feb 1;14(1):17-22. doi: 10.9740/mhc.2024.02.017. eCollection 2024 Feb.
The Psychotropic Drug Safety Initiative (PDSI) is a national Veterans Affairs program that recommends obtaining cardiovascular vital signs semiannually and urine toxicology screening annually for veterans prescribed stimulants. The PDSI also recommends a risk review of concurrent central nervous system (CNS) depressants to ensure the benefits of coadministration with stimulants outweigh the risks. This project's purpose was to evaluate the occurrence of coprescriptions for CNS depressants and stimulants and encourage compliance with the PDSI recommendations to increase safe and appropriate management of veterans prescribed the combination. This study aimed to evaluate the occurrence of coprescriptions for CNS depressants and stimulants, evaluate compliance with stimulant monitoring recommendations, and measure the proportion of pharmacist recommendations implemented by the prescriber.
This quality improvement project identified veterans with an outpatient prescription for a stimulant and any coprescription(s) for benzodiazepines, sedative-hypnotics, and/or opioids. A pharmacy intervention note was generated to request a risk review, provide recommendations for de-escalation, and notify the stimulant prescriber of overdue monitoring parameters. Impact was measured 60 days after intervention. Descriptive statistics and a McNemar test were used to compare preintervention and postintervention data.
From the 61 patients included, there were 67 unique prescriptions for benzodiazepines (49.3%), sedative-hypnotics (34.3%), and opioids (16.4%) in combination with a stimulant. Pharmacist intervention resulted in de-escalation of coprescribing for 9 patients (16.1%) and was associated with statistically significant improvement in compliance to stimulant monitoring recommendations.
Clinical pharmacists can assist in ensuring safe and appropriate monitoring and management of veterans prescribed stimulants.
精神药物安全倡议(PDSI)是一项美国退伍军人事务部的全国性计划,建议为开具兴奋剂处方的退伍军人每半年获取一次心血管生命体征,并每年进行一次尿液毒理学筛查。PDSI还建议对同时使用的中枢神经系统(CNS)抑制剂进行风险评估,以确保与兴奋剂联合使用的益处大于风险。本项目的目的是评估CNS抑制剂和兴奋剂联合处方的发生率,并鼓励遵守PDSI建议,以加强对开具该联合处方的退伍军人的安全和适当管理。本研究旨在评估CNS抑制剂和兴奋剂联合处方的发生率,评估对兴奋剂监测建议的遵守情况,并衡量处方者实施药剂师建议的比例。
本质量改进项目确定了开具兴奋剂门诊处方以及开具苯二氮䓬类、镇静催眠药和/或阿片类药物联合处方的退伍军人。生成一份药房干预记录,要求进行风险评估,提供逐步减少用药的建议,并通知兴奋剂处方者逾期的监测参数。在干预60天后衡量影响。使用描述性统计和McNemar检验比较干预前后的数据。
在纳入的61名患者中,有67张独特的处方,涉及苯二氮䓬类(49.3%)、镇静催眠药(34.3%)和阿片类药物(16.4%)与兴奋剂联合使用。药剂师的干预导致9名患者(16.1%)减少了联合处方用药,并且与兴奋剂监测建议的依从性在统计学上有显著改善相关。
临床药剂师可以协助确保对开具兴奋剂处方的退伍军人进行安全和适当的监测与管理。